Although innovative therapies such as BCMA-directed CAR-T cells and bispecific antibodies have changed the management of relapsed disease [13], MM remains an incurable disease in which most patients continue to experience successive relapses. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.